Skip to content
TrialScanner

NCT02694822

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Phase 1/Phase 2CompletedAGENLead

Registry record

Lead sponsor
Agenus Inc.
Conditions
Advanced Solid Cancers; Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Primary completion
Mar 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02694822 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02694822: AGEN1884, an Anti-CTLA-4... | TrialScanner